ダウンロード数: 861
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
58_647.pdf | 675.53 kB | Adobe PDF | 見る/開く |
タイトル: | 分子標的治療の副作用対策: Everolimus |
その他のタイトル: | Management of Side Effects of Everolimus Treatment for Metastatic Renal Cell Carcinoma |
著者: | 三神, 一哉 本郷, 文弥 三木, 恒治 |
著者名の別形: | Mikami, Kazuya Hongo, Fumiya Miki, Tsuneharu |
キーワード: | Metastatic RCC Everolimus Side effects ILD |
発行日: | Nov-2012 |
出版者: | 泌尿器科紀要刊行会 |
誌名: | 泌尿器科紀要 |
巻: | 58 |
号: | 11 |
開始ページ: | 647 |
終了ページ: | 650 |
抄録: | Treatment with everolimus is known to prolong progression-free survival in patients with renal cell carcinoma resistant against tyrosine-kinase inhibitor therapy. The side effects must be known for more effective use of this drug. Information of side effects was collected from a randomized controlled study, the early post-marketing phase vigilance and from our own experience. Interstitial lung disease (ILD) was a potentially severe side effect. Incidence of ILD was relatively large compared with that of other target therapy agents. Infections, thrombocytopenia, stomatitis and others were experienced as other side effects. However, there were few uncontrollable side effects. Management of side effects of everolimus can be improved by obtaining sufficient knowledge. |
著作権等: | 許諾条件により本文は2013-12-01に公開 |
URI: | http://hdl.handle.net/2433/166341 |
PubMed ID: | 23254794 |
出現コレクション: | Vol.58 No.11 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。